Cambridge firm in-licenses two oncology programmes
Uncategorized
IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients
Phase 1 trial of IRL757 demonstrates good absorption and safety profile
KCL study finds cell ageing could reveal early signs of neurodegenerative disease
Conditions such as Alzheimer’s and Parkinson’s affect over one million people in the UK
Rare chance
The difficulties of identifying and treating rare diseases
Flagged up
How pharma can utilise the power of Nordic real-world data
Turning point
From data to action – the healthcare revolution is gaining momentum
Old moves
The age-old challenge of diversity in clinical studies
Time after time
Overcoming time perception challenges in dementia through technology
Primary goals
How can pharma re-engage with primary care?
Vaccine visionaries
Pierre Morgon is Executive Vice President of Portfolio Strategy and Supranational Affairs, as well as Managing Director Europe, at CanSino Biologics
Dr Know
The ‘Clinician of the Future 2023’ report suggests that healthcare professionals are preparing to embrace generative AI
In sickness and in health?
Fear, loathing and NHS conundrums on the campaign trail!
Mind games
Vitiligo is more than a cosmetic condition
Mission possible
How pharma can help the NHS deliver personalised care
Time travel technicians
Can artificial intelligence replicate the human touch in healthcare provision?
